This is the revision of a competitive renewal for a successful Mental Retardation Research Center (MRRC) in the Civitan International Research Center at the University of Alabama at Birmingham (UAB). The MRRC at DAB builds upon the University's contributions over the past three decades to the field of mental retardation and developmental disabilities. The MRRC's mission is threefold: to increase scientific knowledge about basic developmental neurobiology and factors that affect CNS development;to develop and test preventive interventions for MR/DD;and to advance understanding about effective treatment strategies to ameliorate the personal, familial, and societal consequences of MR/DD. The Center includes 62 participants comprised of 37 investigators who access research core services and another 25 clinicians and scientists who are part of the greater MRRC community but do not access research cores. Investigators from 16 basic science and clinical departments (with 51 funded or pending research projects that will use core supports) will participate. The five major research groups are: (I) Development, function and plasticity of synapses;(II) Molecular biology/genetics of nervous system development and degeneration;(III) CNS infectious diseases and neuroendocrinologic mechanisms;(IV) Diagnosis, interventions and therapies for MR/DD, and (V) Environmental effects on brain development (including behavioral interaction with parent, poverty, peers, and chemicals). An Administration and Biometry Core (Core A) provides scientific leadership, supports population-based studies on mental retardation and neurodevelopmental disabilities, provides database management and biostatistical support, sponsors center-wide scientific seminars and colloquia, encourages innovation and new multidisciplinary collaborations, actively mentors junior MRRC investigators, and oversees administrative functioning. The three research cores are: the Recombinant Technologies Core (Core B), the Developmental Neurobiology Imaging and Tissue Processing Core (Core C), and the Developmental Genomics Core (Core D). Collectively, these cores are designed to promote multidisciplinary collaboration, timely exchange of information and technology advances, attract new investigators to MR/DD research, and promote research activities with other MRRCs, as well as to increase the quality and productivity of funded research projects while demonstrating cost-effectiveness. Of high priority is the inclusion of women and individuals from underrepresented ethnic/racial groups as MRRC scientists, trainees, and participants in research projects.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Center Core Grants (P30)
Project #
5P30HD038985-10
Application #
8318241
Study Section
Special Emphasis Panel (ZHD1-MRG-C (12))
Program Officer
Parisi, Melissa
Project Start
2000-08-04
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2014-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$1,050,405
Indirect Cost
$331,011
Name
University of Alabama Birmingham
Department
Pediatrics
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Butler, Anderson A; Webb, William M; Lubin, Farah D (2016) Regulatory RNAs and control of epigenetic mechanisms: expectations for cognition and cognitive dysfunction. Epigenomics 8:135-51
Heaven, Michael R; Flint, Daniel; Randall, Shan M et al. (2016) Composition of Rosenthal Fibers, the Protein Aggregate Hallmark of Alexander Disease. J Proteome Res 15:2265-82
Robel, Stefanie; Buckingham, Susan C; Boni, Jessica L et al. (2015) Reactive astrogliosis causes the development of spontaneous seizures. J Neurosci 35:3330-45
Tarquinio, Daniel C; Hou, Wei; Neul, Jeffrey L et al. (2015) Age of diagnosis in Rett syndrome: patterns of recognition among diagnosticians and risk factors for late diagnosis. Pediatr Neurol 52:585-91.e2
Tarquinio, Daniel C; Hou, Wei; Neul, Jeffrey L et al. (2015) The Changing Face of Survival in Rett Syndrome and MECP2-Related Disorders. Pediatr Neurol 53:402-11
Robert, Stephanie M; Buckingham, Susan C; Campbell, Susan L et al. (2015) SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. Sci Transl Med 7:289ra86
Cuddapah, Vishnu Anand; Pillai, Rajesh B; Shekar, Kiran V et al. (2014) Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet 51:152-8
Buckingham, Susan C; Ramos, Theresa N; Barnum, Scott R (2014) Complement C5-deficient mice are protected from seizures in experimental cerebral malaria. Epilepsia 55:e139-42
Xu, Xin; Kozikowski, Alan P; Pozzo-Miller, Lucas (2014) A selective histone deacetylase-6 inhibitor improves BDNF trafficking in hippocampal neurons from Mecp2 knockout mice: implications for Rett syndrome. Front Cell Neurosci 8:68
Lucas, Elizabeth K; Dougherty, Sarah E; McMeekin, Laura J et al. (2014) PGC-1α provides a transcriptional framework for synchronous neurotransmitter release from parvalbumin-positive interneurons. J Neurosci 34:14375-87

Showing the most recent 10 out of 123 publications